Researchers at Keck School of Medicine at the University of Southern California have received a five-year grant of up to $3.2 million from NIH to further explore the role of thymulin in inflammaging and cancer, as well as its therapeutic potential.

Sethera Therapeutics and Roswell Park Comprehensive Cancer Center have been awarded funding through the Breast Cancer Research Program Breakthrough Award, administered by the Congressionally Directed Medical Research Programs. 

Traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery do not predict who will benefit more from adding hormone therapy to postoperative radiation, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center. 

As focal therapy gains popularity as a less invasive treatment option for some men with prostate cancer, a national study led by researchers at the University of Pittsburgh found that some men may be receiving treatment that is either unnecessary or not aggressive enough for their cancer. 

Liver cancer experts at 17 cancer centers, part of a consortium of North American experts called HCC-LIVE, have compiled a guidance on the best treatments for hepatocellular carcinoma in North America. 

Researchers at Baylor College of Medicine have developed a drug called CS18 that disrupts the ability of cancer cells to survive therapy. 

The SANRECO phase II trial of divesiran, a first-in-class siRNA, in 48 phlebotomy-dependent patients with polycythemia vera, met its primary endpoint and secondary endpoints. The 36-week, randomized, double-blind, placebo-controlled portion of the trial administered divesiran subcutaneously (6 mg/kg) every six weeks or every twelve weeks. 

FDA granted accelerated approval to iberdomide (Zenbexus) in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy including a proteasome inhibitor and an immunomodulatory agent.

FDA announced a forthcoming hybrid meeting of the Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee on Sept. 23 to discuss, make recommendations, and vote on information regarding the premarket approval application for the Galleri test sponsored by GRAIL, Inc. 

FDA approved Labcorp’s PGDx elio tissue complete CDx as a companion diagnostic to help identify patients with advanced melanoma with certain BRAF variants who may benefit from treatment with FDA-approved targeted therapies.

The Society for Immunotherapy of Cancer announced the recipients of its 2026 Annual Awards, recognizing individuals whose exceptional leadership, scientific achievements and service have helped advance the field of cancer immunotherapy. 

The American College of Surgeons Commission on Cancer has introduced a rural accreditation category to expand access to high-quality cancer care in rural communities, where long travel times and specialist shortages often limit care.

Roswell Park Comprehensive Cancer Center in Buffalo, NY, and Burjeel Medical City, Abu Dhabi, are collaborating to advance thoracic surgical care for patients served by Burjeel Medical City. 

NYU Langone Health and Dana-Farber Cancer Institute have formed a strategic collaboration to co-develop Solavia Decision Suite, an oncology support platform designed to improve cancer care for patients and clinicians. 

Dana-Farber Cancer Institute’s Department of Pathology, in collaboration with Brigham and Women’s Hospital, has received renewed funding for the Ruth L. Kirschstein NRSA Institutional Research Training Grant from the NCI, providing resources for pathology residents, clinical fellows, and PhD-trained scientists pursuing research careers in cancer pathology.

The phase III XPORT-EC-042 trial, evaluating selinexor as a maintenance-only therapy compared to placebo in adult patients with TP53 wild-type advanced or recurrent endometrial cancer, did not meet its primary endpoint of progression free survival. 

Women who test negative for BRCA gene mutations may still be at greater risk of developing breast cancer than the general population, according to a study led by investigators at Cedars-Sinai Medical Center, the University of Toronto, and the University of Sydney. 

Researchers at the Johns Hopkins Kimmel Cancer Center validated an artificial intelligence-powered blood test that accurately detected liver cancer in people from two geographically and biologically distinct populations and also uncovered the underlying biological signals that make the test effective.

Mesothelioma cells have a survival trick. When researchers exposed them to an experimental drug that targeted one of the cancer’s main growth switches, the cells didn’t die. Instead, they found a way around the drug’s effect.

An open resource of patient-derived cancer models has enabled researchers to create the first large-scale map of the genes that cancers rely on to survive, offering new routes for research into better and less toxic treatments for patients.

Researchers at the University of Kansas Cancer Center, Emory University School of Medicine, and the international Southwest Oncology Group Cancer Research Network have identified a blood biomarker that may help thousands of women with hormone receptor-positive breast cancer avoid unnecessary chemotherapy.

While Black and Hispanic families are enthusiastic about research participation, other provider- and systems-focused factors may influence their involvement in pediatric oncology clinical trials, according to a study led by researchers at UT Southwestern Medical Center and Dana-Farber/Mass General.

FDA approved Pluvicto (lutetium Lu 177 vipivotide tetraxetan) in combination with an androgen receptor pathway inhibitor for patients with prostate-specific membrane antigen-positive metastatic androgen pathway modulation-naive/sensitive prostate cancer, commonly known as metastatic hormone-sensitive prostate cancer.

The National Cancer Institute approved the following clinical research studies last month. 

UW Health officially began offering proton therapy at Eastpark Medical Center. 

Researchers have found that a combination of enfortumab vedotin and pembrolizumab helps patients with muscle-invasive bladder cancer live longer while reducing the risk that their cancer will return after surgery, according to the results of an international phase III clinical trial.

A team of investigators have uncovered a rare genetic mutation that enables some blood cancers to evade both approved Bruton tyrosine kinase inhibitors and newer BTK degraders.

Researchers at the Salk Institute and Arc Institute and their collaborators unveiled the first body-wide single-cell atlas of two major epigenetic systems: three-dimensional genome folding and DNA methylation—precise patterns of methyl chemical groups tacked onto DNA—measured simultaneously in the same cells.

Cancer immunotherapies have transformed treatment for many cancers, but pancreatic cancer remains especially difficult to treat. 

Researchers at Moffitt Cancer Center have developed a chemical approach that could help make targeted cancer medicines safer and more precise.

FDA’s Cellular, Tissue, and Gene Therapies Advisory Committee voted 10:3 in favor of Replimune’s Biologics License Application for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma.

The European Medicines Agency’s Committee for Medicinal Products for Human Use adopted positive opinions, recommending the granting of marketing authorizations, for two biosimilar medicines in oncology: Ascend’s Denosumab Ascend and Qilu’s Nylaspeg.

HHS and the Centers for Medicare & Medicaid Services deferred more than $1 billion in federal Medicaid payments to California and Minnesota as these states submit additional documentation supporting certain Medicaid claims. 

HHS has joined President Trump’s “Genesis Mission,” an artificial intelligence platform to harness federal scientific datasets. The purpose of the move is to use AI to further Robert F. Kennedy Jr.’s efforts to end what he calls “the chronic disease crisis,” a focal point of his Make America Healthy Again strategy. 

Marlon L. Wong, associate professor of clinical physical therapy at the University of Miami Miller School of Medicine, was awarded a grant from Gabrielle’s Angel Foundation for Cancer Research. The three-year, $225,000 award will support research focused on improving quality of life for patients living with chemotherapy-induced peripheral neuropathy and other long-term effects of cancer treatment.

The University of New Mexico Comprehensive Cancer Center has installed an MRI-linear accelerator.

Two drug combinations, Tecvayli (teclistamab-cqyv) + Talvey (talquetamab-tgvs), a BCMA and GPRC5D dual antigen targeting regimen, and Talvey + pomalidomide (Pomalyst, sponsored by Bristol Myers Squibb), demonstrated statistically significant and clinically meaningful improvements in progression-free survival and overall survival compared with investigator’s choice standard of care for adult patients with relapsed or refractory multiple myeloma who received 1 to 4 prior lines of therapy, including an anti-CD38 antibody and lenalidomide. 

Just days after a single treatment, patients experienced dramatic reductions in their tumors, with one patient achieving near-complete tumor regression, according to the results of a phase I study conducted by researchers at Mass General Cancer Center. 

Repeat testing is tied to earlier diagnoses and shaped by health-system outreach, according to a retrospective cohort study of nearly 500,000 adults. 

Scientists at The Wistar Institute have identified a mechanism behind the chemotherapy resistance that makes ovarian cancer so lethal. The researchers showed that chemotherapy triggers an inflammatory cascade that recruits immune cells into the tumor microenvironment, which ultimately function to protect the cancer from subsequent chemotherapy. 

Biological sex factors into cancer in ways you might not expect. In lung cancer, a form called squamous cell carcinoma disproportionately affects males while adenocarcinoma occurs more frequently in females.

A study, which focused on the DNA switches of prostate cancer cells, reveals insights into enhancers that become active during cancer development and turn on genes linked to the disease. The study found that enhancers work cooperatively in 3D networks, rather than as isolated switches. Some enhancers function as “central hubs” that control many genes, while others play a supporting role. These findings could help with the development of targeted cancer therapies.

Chronic, low-grade inflammation in the body—a phenomenon known as “inflammaging” because it increases with age—has been linked to many leading causes of illness and death, including cancer, heart disease, metabolic conditions, and neurodegenerative diseases. But scientists have struggled to understand what causes inflammaging or how to reverse its effects.

Obesity can act as fuel for leukemia, according to a study led by Indiana University School of Medicine scientists. To help many patients facing aggressive blood cancers overcome this metabolic risk, researchers identified a potential new treatment strategy that combines popular weight-loss medications with anti-inflammatory drugs. 

FDA approved Jideytro (zidesamtinib), a ROS1 selective inhibitor, for the treatment of adult patients with locally advanced or metastatic ROS1-positive non-small cell lung cancer who received a prior ROS1 kinase inhibitor. 

FDA accepted for Priority Review a supplemental New Drug Application for Talzenna (talazoparib), an oral poly ADP-ribose polymerase inhibitor, in combination with Xtandi (enzalutamide), an androgen receptor pathway inhibitor, in men with homologous recombination repair gene-altered metastatic castration-sensitive prostate cancer, also known as metastatic hormone-sensitive prostate cancer. 

Alpha1H has received regulatory approval from the European Medicines Agency for its phase III clinical study of the therapy in bladder cancer. The approval represents a milestone for the clinical development of Alpha1H and provides a clear regulatory path toward a potential future marketing application in Europe.